Quantinno Capital Management LP Has $1.73 Million Stock Holdings in Haemonetics Corporation $HAE

Quantinno Capital Management LP lifted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 438.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,708 shares of the medical instruments supplier’s stock after purchasing an additional 25,000 shares during the period. Quantinno Capital Management LP’s holdings in Haemonetics were worth $1,731,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in shares of Haemonetics during the 1st quarter worth approximately $2,435,000. North Peak Capital Management LLC grew its position in shares of Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares during the period. Aurora Investment Counsel bought a new stake in shares of Haemonetics in the 1st quarter valued at $1,217,000. London Co. of Virginia increased its stake in shares of Haemonetics by 33.9% in the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock valued at $19,884,000 after acquiring an additional 89,242 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

NYSE HAE opened at $87.16 on Wednesday. The company has a market cap of $3.97 billion, a P/E ratio of 42.73, a PEG ratio of 1.74 and a beta of 0.52. The company has a fifty day simple moving average of $77.78 and a 200 day simple moving average of $66.71. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $88.88.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same quarter in the previous year, the firm earned $1.10 earnings per share. Haemonetics’s quarterly revenue was up 5.5% on a year-over-year basis. Sell-side analysts predict that Haemonetics Corporation will post 5.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Raymond James Financial reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Haemonetics in a research note on Friday. BTIG Research upped their price objective on shares of Haemonetics from $84.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Robert W. Baird set a $96.00 price objective on shares of Haemonetics in a research report on Friday. Finally, Barrington Research set a $95.00 price objective on shares of Haemonetics in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $90.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.